Navire Pharma Inc. clinical trials

A subsidiary of BridgeBio

The registry lists 3 studies whose lead sponsor is Navire Pharma Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 12, 2024.

Status

Terminated: 3

Phase

Phase 1: 3

Where

United States: 2
Greece: 1
Denmark: 1
France: 1
Spain: 1
Australia: 1

Registry sponsor names on this page

Navire Pharma Inc., a BridgeBio company3 studies

Something wrong with this grouping? Tell us on the BridgeBio page.

Studies

Recruiting first, then most recently updated. Showing 3 of 3. All BridgeBio studies →

SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C MutationTerminatedNCT05480865Phase 1
Sponsor listed in the registry: Navire Pharma Inc., a BridgeBio company
First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid TumorsTerminatedNCT04528836Phase 1
Sponsor listed in the registry: Navire Pharma Inc., a BridgeBio company
SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS MutationTerminatedNCT05375084Phase 1
Sponsor listed in the registry: Navire Pharma Inc., a BridgeBio company